TPMT genotype, phenotype and thiopurine metabolites (527)

This external quality assessment scheme is aimed for clinical laboratories performing TPMT investigations and/or analysis of thiopurine metabolites. The purpose is to evaluate the participants' analysis results for the included components, by comparison with results from other participants and in the long terms contributing to comparable results between laboratories. Participating laboratories may choose to report result for one or more of the included examinations. In addition, an interpretation of the results can also be submitted.

The test material consists of frozen human whole blood with accompanying information about the level of B—Hemoglobin, B—RBC and B—Hct.

Test material: 1 /round for analysis of DNA—TPMT genotype and B—TPMT activity 
1 /round for analysis of B—6-MMPN and B—6-TGN. 

Frequency: 2/year 

Reports: Normally within two months from closing date.

Examinations 
DNA—TPMT:c.238G>C (NM_000367.5, NG_012137.3) 

DNA—TPMT:c.460G>A (NM_000367.5, NG_012137.3) 

DNA—TPMT:c.719A>G (NM_000367.5, NG_012137.3) 

DNA—TPMT genotype according to *-nomenclature 

B—TPMT activity (nmol/gHb*h) 

B—6-MMPN (pmol/8*10^8Erc)

B—6-TGN (pmol/8*10^8Erc)  

Last date of registration: 2024-12-01 (for participation in round 2025:01)

Price: 461 EUR (dry ice and shipping cost included)

Swedish laboratories register on our Swedish site. Laboratories from Denmark or Norway register through their national distributors, DEKS (Denmark) or Noklus (Norway). Laboratories from other countries can send an application to participate as international participants.